2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1729

Increased Serum Levels of Micro-RNA 30d and Micro-RNA 423-5p in 2 Independent Cohorts of Patients with Morphea

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 1071

Increased Susceptibility of SLE-Prone Mice to Pulmonary Haemophilus Influenzae Infection Was Attributed to Dysfunctions of Innate Immune Responses

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1095

Increasing Lipid Panel Monitoring in a Rheumatology Clinic

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 994

Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1293

Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1641

Indications for Initial Renal Biopsy in Systemic Lupus Erythematosus: A Systematic Review of the Literature

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1462

Induction of Immune Tolerance through an Epitope-Specific Vaccine Induces Clinical Amelioration in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1542

Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1223

Inflammatory Bowel Diseases and the Risks of Fracture and Low Mineral Density: Review of the Literature and Meta-Analysis of Observational Cohorts

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1450

Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 1315

Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1039

Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity

Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1705

Inhibition of EZH2 Stops Fibrosis and Improves Angiogenesis in Scleroderma

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 956

Inhibition of Fucosylation in Endothelial Cells Reduces Rheumatoid Arthritis Angiogenesis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

9:00AM-11:00AM: Abstract Number: 1714

Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].